



RECEIVED
JUL 18 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of DEBINSKI

Application No.: 09/226,790

Date filed: January 7, 1999


Examiner: Ungar, S.

Group: 1642

For: METHOD FOR DIAGNOSING, IMAGING, AND TREATING TUMORS USING
RESTRICTIVE RECEPTOR FOR INTERLEUKIN-13

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with
the U.S. Postal Service as First Class mail in an envelope
addressed to the Commissioner for Patents, Washington, D.C.
20231, on July 13, 2001.


Stanley A. Kim, Esq., Reg. No. 42,730

Commissioner for Patents
Washington, DC 20231

DECLARATION UNDER 37 C.F.R. §1.132

I, James R. Connor, Ph.D., declare that:

1. Waldemar Debinski, M.D., Ph.D., ("Dr. Debinski") and I are the coinventors of
the subject matter described and claimed in the above-identified U.S. patent application.

2. I am a coauthor of the subject matter disclosed in Debinski et al., Abstract: A
Restrictive Receptor for Interleukin 13 is a Marker and Therapeutic Target for Human
Glioblastoma Multiforme, The Society for Neuro-Oncology Third Annual Meeting: Abstract
Form November 12-15, 1998, San Francisco, CA ("the 1998 Abstract"). The 1998 Abstract also
names D. M. Gibo, S.W. Hulet, Dr. Connor, and G.Y. Gillespie as coauthors. Of the five

coauthors of the 1998 Abstract, only Dr. Debinski and I are coinventors of the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application. The other coauthors are not coinventors, but rather assisted with conventional techniques under Dr. Debinski's and my direction.


3. Denise M. Gibo, a research assistant, assisted with experiments that Dr. Debinski and I designed by preparing tissue sections and performing autoradiography. She did not make an inventive contribution to the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application.

4. Stanley W. Hulet, a graduate student under my supervision, performed autoradiograph experiments that Dr. Debinski and I designed. He did not make an inventive contribution to the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application.


5. Dr. G.Y. Gillespie, a recognized expert in the field of brain tumors, provided glioblastoma samples used in the studies reported in the 1998 abstract and assisted in experiments with animal models of intracranial glioblastoma using the cytotoxins described therein. He did not make an inventive contribution to the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application.

I further declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

7-12-01
Date


James Connor, Ph.D.

P1007328;1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of DEBINSKI

Application No.: 09/226,794

Date filed: January 7, 1999



Examiner: Ungar, S.


Group: 1642

For: METHOD FOR DIAGNOSING, IMAGING, AND TREATING TUMORS USING
RESTRICTIVE RECEPTOR FOR INTERLEUKIN 13

#16
J.G.J.
7/24/01

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with
the U.S. Postal Service as First Class mail in an envelope
addressed to the Commissioner for Patents, Washington, D.C.
20231, on July 13, 2001.


Stanley A. Kim, Esq., Reg. No. 42,730

Commissioner for Patents
Washington, DC 20231

DECLARATION UNDER 37 C.F.R. §1.132

I, Waldemar Debinski, M.D., Ph.D., declare that:

1. James R. Connor, Ph.D., ("Dr. Connor") and I are the coinventors of the subject
matter described and claimed in the above-identified U.S. patent application.

2. I am a coauthor of the subject matter disclosed in Debinski et al., Abstract: A
Restrictive Receptor for Interleukin 13 is a Marker and Therapeutic Target for Human
Glioblastoma Multiforme, The Society for Neuro-Oncology Third Annual Meeting: Abstract
Form November 12-15, 1998, San Francisco, CA ("the 1998 Abstract"). The 1998 Abstract also
names D. M. Gibo, S.W. Hulet, Dr. Connor, and G.Y. Gillespie as coauthors. Of the five

coauthors of the 1998 Abstract, only Dr. Connor and I are coinventors of the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application. The other coauthors are not coinventors, but rather assisted with conventional techniques under Dr. Connor's and my direction.

3. Denise M. Gibo, a research assistant, assisted with experiments that Dr. Connor and I designed by preparing tissue sections and performing autoradiography. She did not make an inventive contribution to the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application.

4. Stanley W. Hulet, a graduate student, performed autoradiograph experiments that Dr. Connor and I designed. He did not make an inventive contribution to the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application.

5. Dr. G.Y. Gillespie, a recognized expert in the field of brain tumors, provided glioblastoma samples used in the studies reported in the 1998 abstract and assisted in experiments with animal models of intracranial glioblastoma using the cytotoxins described therein. He did not make an inventive contribution to the subject matter disclosed in the 1998 Abstract used to reject the claims pending in the above-identified patent application.

I further declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

7/12/01
Date

W. DeBinski
Waldermar DeBinski, M.D., Ph.D.

PI007269;1

-3-

** TOTAL PAGE.07 **